Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Orders Label Revisions for Otezla, Ceftriaxone
August 3, 2018
- Fusion of Registry Network and MID-NET Will Change Clinical Trial Landscape in Japan: MHLW Official
July 31, 2018
- Inappropriate Drug Promotion at Clinics Involves Encouragement of Off-Label Use in Most Cases: Study
July 31, 2018
- Boehringer’s DPP-4/SGLT2 Combo Clears MHLW Panel
July 30, 2018
- Govt Revises Basic Policy of Asia Health Initiative, with New Focus on Promoting Access to Drugs in Asia
July 27, 2018
- MHLW Panel Wraps Up 1st Round of Debates on PMD Law Amendment, Elaborate Discussions Slated to Start in September
July 26, 2018
- MHLW Shuffles Senior Bureaucrats, Health Insurance Chief Suzuki Tapped for Top Post
July 25, 2018
- AMED Launches Study on Evaluating the Quality and Safety of Nucleic Acid Medicines to Promote Their Development
July 25, 2018
- Discussions Needed for “Biosame” Products: MHLW Official
July 24, 2018
- Lilly’s Breast Cancer Med Abemaciclib Up for MHLW Panel Review on Aug. 3
July 23, 2018
- Lawmakers Question Rationale for PMD Law Amendment as LDP Launches Debate
July 19, 2018
- Scope of Japan-EU GMP Mutual Recognition Agreement for Pharmaceuticals Expanded: MHLW
July 19, 2018
- Boehringer’s DPP-4/SGLT2 Combo Up for MHLW Panel Review on July 27
July 17, 2018
- MHLW to Introduce Guidelines for Sales Reps’ Activities, Calling for the Creation of Supervising Offices
July 17, 2018
- New Medical Infrastructure Law to Pave Way for Database on 50 Million People: Govt Official
July 13, 2018
- MHLW Orders Removal of Pregnancy Contraindications for 3 Immunosuppressants
July 12, 2018
- MHLW Selects 9 Priority Prefectures for Generic Promotion Project, but Leaves Tokyo Out
July 12, 2018
- Generic Makers Should Shift to Biologics Biz for Survival: MHLW Official
July 11, 2018
- MHLW Official Expounds on “Authorized Biosimilar” Pricing, 50% Generic Rule Applies for “Biosame” Products
July 11, 2018
- Cabinet OKs FY2019 Budget Guidelines, Allows Request for 600 Billion Yen Social Security Cost Rise
July 11, 2018
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…